Generally, medical management of men with BPH begins with a trial of tamsulosin (a selective alpha-1 antagonist) with the potential to progress to combination therapy depending on a patient’s response and symptoms. This evidence concerns the gene PSMA6 and benign prostatic hyperplasia.